MDG-1011

N/A

Report date: 2023/02/23 16:01:46

Base Information

Drug NameMDG-1011
Drug Alias NameMDG-1011
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsMelanoma antigen recognized by T-cells 1 modulators
TargetsMelanoma antigen recognized by T-cells 1
Therapy Area/IndicationsMyelodysplastic Syndromes
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesMax Delbrück Center For Molecular MedicineHelmholtz Zentrum Munchen
China Registration ClassN/A

Develop Information

Active CompaniesHelmholtz Zentrum MunchenMax Delbrück Center For Molecular MedicineMedigene Ag
Inactive CompaniesN/A
Active IndicationsMyelodysplastic Syndromes
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A